Medicare drug price rule may target under-the-skin Keytruda and Opdivo

Medicare drug price rule may target under-the-skin Keytruda and Opdivo is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Jonathan Gardner · 2026-06-15

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

Source: BioPharma Dive